BioCentury | Oct 1, 2007
Company News

Intronn, Virxsys deal

...all the core technology and preclinical programs of Intronn for an undisclosed amount of stock. Intronn's...
...The product is in Phase II testing to treat HIV. Further terms were not disclosed. Intronn Inc....
BioCentury | Feb 26, 2007
Company News

Virxsys management update

...Hired: Gerard McGarrity as EVP of scientific and clinical affairs, formerly president and CEO of Intronn Inc. WIR...
BioCentury | Jun 13, 2005
Clinical News

Intronn preclinical data

...levels. Data were presented at the American Society of Gene Therapy meeting in St. Louis. Intronn Inc....
BioCentury | Oct 28, 2004
Politics & Policy

Otto to direct FDA's gene/cell therapy office

...the Center for Biologic Evaluation and Research. Otto was previously COO of gene/cell therapy company Intronn...
BioCentury | Mar 8, 2004
Company News

Intronn, Isogenis Inc. deal

...use its SMaRT spliceosome-mediated RNA trans-splicing technology in combination with Isogenis' veto gene delivery technology. Intronn Inc....
BioCentury | Jul 14, 2003
Company News

Intronn other research news

...allows the cell's own splicing mechanisms to replace the mutated portion with the corrected message. Intronn Inc....
BioCentury | Jan 20, 2003
Company News

Intronn management update

Intronn Inc. , Rockville, Md. Business: Gene/Cell therapy Hired: Diane Greene as VP of business development, formerly director of marketing at Celera Genomics Group WIR Staff...
BioCentury | Apr 8, 2002
Company News

Intronn management update

Intronn Inc., Rockville, Md. Business: Gene/Cell therapy Hired: Edward Otto as COO, formerly COO at Novartis Corp.'s Genetic Therapy Inc. subsidiary WIR Staff...
BioCentury | Jan 7, 2002
Company News

Intronn other research news

...but noted that a different vector could be used to deliver the CFTR-PTM more effectively. Intronn Inc....
BioCentury | Jul 2, 2001
Company News

Intronn LLC other research news

...Kidney Diseases to develop its SMaRT technology to repair the genetic defect in cystic fibrosis. Intronn...
Items per page:
1 - 10 of 23
BioCentury | Oct 1, 2007
Company News

Intronn, Virxsys deal

...all the core technology and preclinical programs of Intronn for an undisclosed amount of stock. Intronn's...
...The product is in Phase II testing to treat HIV. Further terms were not disclosed. Intronn Inc....
BioCentury | Feb 26, 2007
Company News

Virxsys management update

...Hired: Gerard McGarrity as EVP of scientific and clinical affairs, formerly president and CEO of Intronn Inc. WIR...
BioCentury | Jun 13, 2005
Clinical News

Intronn preclinical data

...levels. Data were presented at the American Society of Gene Therapy meeting in St. Louis. Intronn Inc....
BioCentury | Oct 28, 2004
Politics & Policy

Otto to direct FDA's gene/cell therapy office

...the Center for Biologic Evaluation and Research. Otto was previously COO of gene/cell therapy company Intronn...
BioCentury | Mar 8, 2004
Company News

Intronn, Isogenis Inc. deal

...use its SMaRT spliceosome-mediated RNA trans-splicing technology in combination with Isogenis' veto gene delivery technology. Intronn Inc....
BioCentury | Jul 14, 2003
Company News

Intronn other research news

...allows the cell's own splicing mechanisms to replace the mutated portion with the corrected message. Intronn Inc....
BioCentury | Jan 20, 2003
Company News

Intronn management update

Intronn Inc. , Rockville, Md. Business: Gene/Cell therapy Hired: Diane Greene as VP of business development, formerly director of marketing at Celera Genomics Group WIR Staff...
BioCentury | Apr 8, 2002
Company News

Intronn management update

Intronn Inc., Rockville, Md. Business: Gene/Cell therapy Hired: Edward Otto as COO, formerly COO at Novartis Corp.'s Genetic Therapy Inc. subsidiary WIR Staff...
BioCentury | Jan 7, 2002
Company News

Intronn other research news

...but noted that a different vector could be used to deliver the CFTR-PTM more effectively. Intronn Inc....
BioCentury | Jul 2, 2001
Company News

Intronn LLC other research news

...Kidney Diseases to develop its SMaRT technology to repair the genetic defect in cystic fibrosis. Intronn...
Items per page:
1 - 10 of 23